Geron shares plunge as J&J assesses another setback for imetelstat
Geron managed to sorely disappoint investors this morning, watching its share price $GERN plunge 27% after investigators at J&J cut loose a low dose of their partnered cancer drug imetelstat and suspended enrollment on the high end until it gets a better look at more mature data from patients who have already been treated.
The company says that the low 4.7 mg/kg dosing arm registered a disappointing response, adding that those patients would be given a chance to transfer to the 9.4 mg/kg dose.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
